https://biobriefs.com/lilly-backs-recombinase-editing-seamless
Lilly backs recombinase editing — Seamless deal targets genetic hearing loss | BioBriefs
Jan 29, 2026 - Eli Lilly licensed Seamless Therapeutics’ recombinase gene editing platform in a collaboration worth up to roughly $1.12 billion to develop precision genetic...
hearing losslillybacksrecombinaseediting
https://www.ncbi.nlm.nih.gov/Structure/pdb/2FPL
2FPL: RadA recombinase in complex with AMP-PNP and low concentration of K+
DNA repair and recombination protein radAMAGNESIUM IONPHOSPHOAMINOPHOSPHONIC ACID-ADENYLATE ESTERPOTASSIUM ION
radarecombinasecomplexamppnp